GABAB Receptor-Activated Inwardly Rectifying Potassium Current in Dissociated Hippocampal CA3 Neurons

Total Page:16

File Type:pdf, Size:1020Kb

GABAB Receptor-Activated Inwardly Rectifying Potassium Current in Dissociated Hippocampal CA3 Neurons The Journal of Neuroscience, October 15, 1996, 16(20):6374–6385 GABAB Receptor-Activated Inwardly Rectifying Potassium Current in Dissociated Hippocampal CA3 Neurons Deborah L. Sodickson and Bruce P. Bean Vollum Institute, Oregon Health Sciences University, Portland, Oregon 97201, and Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02115 GABA and the GABAB receptor agonist baclofen activated a constant of ;1 sec. GABA activated the potassium conduc- potassium conductance in acutely dissociated hippocampal tance with a half maximally effective concentration (EC50)of1.6 CA3 neurons. Baclofen-activated current required internal GTP, mM, much lower than that for activation of GABAA receptor- was purely potassium selective, and showed strong inward activated chloride current in the same cells (EC50 ;25 mM). At rectification. As with acetylcholine-activated current in atrial low GABA concentrations, activation of the GABAB current had 1 myocytes, external Cs blocked inward but not outward cur- a Hill coefficient of 1.4–2.1, suggesting cooperativity in the 21 rent in a highly voltage-dependent manner, whereas Ba receptor-to-channel pathway. Although the maximal conduc- blocked with no voltage dependence. Unlike the cardiac cur- tance activated by GABAB receptors is much smaller than that rent, however, the baclofen-activated current showed no intrin- activated by GABA receptors, its higher sensitivity to GABA sic voltage-dependent relaxation. With fast solution exchange, A and slower time course make it well suited to respond to low current was activated by baclofen or GABA with a lag of ;50 concentrations of extra-synaptic GABA. msec followed by an exponential phase (time constant ;225 msec at saturating agonist concentrations); deactivation was Key words: baclofen; G-protein; GIRK; GABA; GABAA; chlo- preceded by a lag of ;150 msec and occurred with a time ride current; cesium; barium Two major postsynaptic conductances activated by GABA exist in has been described (Dascal et al., 1993; Kubo et al., 1993; Lesage central neurons. One is a chloride conductance activated by et al., 1994; Doupnik et al., 1995; Krapivinsky et al., 1995b). Both GABAA receptors and is present in virtually all central neurons. native channels and cloned channels seem to be activated by The second is a less widely distributed potassium conductance binding of bg subunits of G-proteins (Logethetis et al., 1987; activated by GABAB receptors (Ga¨hwiler and Brown, 1985; New- Reuveny et al., 1994; Wickman et al., 1994; Huang et al., 1995; berry and Nicoll, 1985; Dutar and Nicoll, 1988). In neurons that Inanobe et al., 1995; Krapivinsky et al., 1995b; Oh et al., 1995). possess both receptors postsynaptically, the requirements for ac- G-protein a subunits may modulate the activation (Schreibmayer tivation are often strikingly different, with GABAB-mediated in- et al., 1996) or help mediate coupling to specific transmitter hibitory postsynaptic potentials requiring stronger or more sus- receptors (Huang et al., 1995). tained stimulation than GABA -mediated responses (Dutar and A Detailed characterization of the GABA -activated potassium Nicoll, 1988; Otis and Mody, 1992). The reasons for this are not B channels in hippocampal neurons has been hindered by lack of a clearly understood. suitable single-cell preparation. Experiments using tissue slices In hippocampal pyramidal neurons, the GABA -activated po- B are limited by the difficulty of making rapid solution changes. For tassium conductance is inwardly rectifying (Ga¨hwiler and Brown, 1985) and mediated by G-proteins (Andrade et al., 1986; Thal- unknown reasons, the conductance is absent or minimal in con- mann, 1988; Thompson and Ga¨hwiler, 1992a) and can be blocked ventional hippocampal tissue culture preparations (Harrison, by external Ba21 ions (Newberry and Nicoll, 1985; Misgeld et al., 1990; Yoon and Rothman, 1991; Pfrieger et al., 1994), although it 1989). These properties are shared by transmitter-activated po- is preserved in organotypic cultures (Ga¨hwiler and Brown, 1985). tassium currents present in various other neurons (North et al., Even such basic properties as the dose–response relationship for 1987; North, 1989; Nicoll et al., 1990) as well as in cardiac atrial GABA and kinetics of current activation are unknown. Knowl- myocytes, where detailed characterization has been possible edge of such properties should help in understanding the differ- (Hartzell, 1988). A family of cDNAs encoding subunits of ences in synaptic activation of GABAA and GABAB receptors. G-protein-activated inward-rectifier potassium (GIRK) channels Acutely isolated cells have been used previously to study serotonin-activated potassium current in dorsal raphe neurons (Penington et al., 1993a). Stimulated by this, we found that robust Received May 31, 1996; revised July 26, 1996; accepted July 30, 1996. GABA receptor-activated potassium currents can be recorded in This work was supported by National Institutes of Health Grant HL35034. We B thank David Cardozo for advice, and Gabriela Greif, Craig Jahr, Stefan a preparation of acutely dissociated hippocampal CA3 neurons McDonough, Indira Raman, Gary Westbrook, and John Williams for comments on that permits rapid solution changes. We characterized the kinet- this manuscript. Correspondence should be addressed to Deborah Sodickson, Volen Center, ics, rectification, ionic block, and GABA dependence of the cur- Brandeis University, 415 South Street, Waltham, MA 02254. rent. The results show that the slow kinetics of GABAB-mediated Bruce Bean’s present address: Department of Neurobiology, Harvard Medical School, 220 Longwood Avenue, Boston, MA 02115. inhibitory postsynaptic currents are primarily attributable to ki- Copyright q 1996 Society for Neuroscience 0270-6474/96/166374-12$05.00/0 netics of receptor-to-channel coupling and that activation of • Sodickson and Bean GABAB-Activated Potassium Current J. Neurosci., October 15, 1996, 16(20):6374–6385 6375 GABAB receptors requires very low levels of extracellular GABA, perhaps near background levels. MATERIALS AND METHODS Preparation of freshly dissociated neurons. Hippocampi from 7- to 12-d-old Long Evans rats were dissected in ice-cold, oxygenated dissociation solution containing (in mM): 82 Na2SO4,30K2SO4, 5 MgCl2, 10 HEPES, 10 glucose, and 0.001% phenol red indicator, pH 7.4. Slices were cut 400 mM thick and incubated for 9 min at 378C in dissociation solution containing 3 mg/ml protease (Type XXIII, Sigma, St. Louis, MO). En- zyme solution was then replaced with dissociation solution containing 1 mg/ml trypsin inhibitor and 1 mg/ml bovine serum albumin, and the slices were allowed to cool to room temperature under an oxygen atmosphere. As cells were needed, slices were withdrawn, and the CA3 region was dissected out and triturated to release individual cells. Cells were placed in the recording chamber in Tyrode’s solution containing (in mM): 150 NaCl, 4 KCl, 2 CaCl2, 2 MgCl2, 10 glucose, and 10 HEPES, pH 7.4 with NaOH. Cells were used within 6–8 hr of slice preparation. CA3 pyramidal neurons were identified morphologically, based on size and shape. Cells identified as pyramidal neurons had a large pyramidal- shaped cell body (12–16 m width, 20–36 m length) with a thick apical dendritic stump (4–6 m width, 18–24 m length) and, in some neurons, one to four basal dendritic stumps (1–4 m width, 6–14 m length). Average cell capacitance was 23 6 5pF(n5125; range, 15–38 pF). Despite the presence of dendritic stumps, the cells behaved as if they were electro- tonically compact: capacity transients settled with a single time constant of 200–350 msec. Whole-cell voltage-clamp recordings. Patch pipettes were pulled from 100 ml Boralex micropipettes (Dynalab, Rochester, NY.). Pipette resis- Figure 1. Dose-dependent activation of current by baclofen applied to tances ranged from 2 to 5 MV when filled with internal solution contain- hippocampal CA3 neurons. A, Inward current elicited at a holding poten- ing (in mM): 108 KH PO , 4.5 MgCl , 9 HEPES, 9 EGTA, 14 mM creatine 2 4 2 tial of 292 mV by successive application of 500 nM,1mM,5mM, and 100 phosphate (Tris salt), 4 mM Mg-ATP, and 0.3 mM GTP (Tris salt), pH 1 1 mM baclofen, with 60 mM external K and 243 mM internal K . B, adjusted to 7.4 with 135.4 mM KOH. The creatine phosphate ATP and Dose–response relationship for baclofen activation of current. Symbols GTP were added from 103 concentrated aliquots stored at 2708C. To and error bars represent mean 6 SEM for determinations in nine cells for prevent nucleotide hydrolysis, the final internal solution was kept on ice 500 nM to1mMbaclofen and four cells for 100 nM baclofen. The response after phosphates were added. at each baclofen concentration was normalized to the maximal response The liquid junction potential between the internal solution and Ty- obtained with 100 mM or1mMbaclofen. The full series of seven or eight rode’s solution (in which the current was zeroed before obtaining a seal) agonist concentrations was preceded and followed by applications of 50 was 12 mV, measured as described by Neher (1992). Membrane poten- 2 mM baclofen, and results were used only if these responses differed by tials were corrected for this junction potential. ,20%. The line is the best least-squares fit to 1/(1 1 EC50 /[baclofen]), Seals were formed and the whole-cell configuration was obtained in where EC is the half-maximally effective concentration of baclofen. EC bath Tyrode’s solution. The cell was then bathed by a gravity-driven, 50 50 5 3 mM. External solution: 60 mM KCl, 94 mM NaCl, 2 mM CaCl ,10mM constant stream of external solution flowing through microcapillary per- 2 HEPES, 2 mM MgCl ,10mMglucose, pH 7.4 with KOH, 3 mM TTX. fusion pipes positioned directly in front of the cell. The perfusion pipes 2 consisted of a linear array of 12 microcapillary tubes of internal diameter 200 m or 250 m, glued together side by side and fed from separate neurons, baclofen inhibits voltage-dependent calcium current as well as reservoirs.
Recommended publications
  • Association of Hypertensive Status and Its Drug Treatment with Lipid and Haemostatic Factors in Middle-Aged Men: the PRIME Study
    Journal of Human Hypertension (2000) 14, 511–518 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Association of hypertensive status and its drug treatment with lipid and haemostatic factors in middle-aged men: the PRIME Study P Marques-Vidal1, M Montaye2, B Haas3, A Bingham4, A Evans5, I Juhan-Vague6, J Ferrie`res1, G Luc2, P Amouyel2, D Arveiler3, D McMaster5, JB Ruidavets1, J-M Bard2, PY Scarabin4 and P Ducimetie`re4 1INSERM U518, Faculte´ de Me´decine Purpan, Toulouse, France; 2MONICA-Lille, Institut Pasteur de Lille, Lille, France; 3MONICA-Strasbourg, Laboratoire d’Epide´miologie et de Sante´ Publique, Strasbourg, France; 4INSERM U258, Hoˆ pital Broussais, Paris, France; 5Belfast-MONICA, Department of Epidemiology, The Queen’s University of Belfast, UK; 6Laboratory of Haematology, La Timone Hospital, Marseille, France Aims: To assess the association of hypertensive status this effect remained after multivariate adjustment. Cal- and antihypertensive drug treatment with lipid and hae- cium channel blockers decreased total cholesterol and mostatic levels in middle-aged men. apoproteins A-I and B; those differences remained sig- Methods and results: Hypertensive status, antihyperten- nificant after multivariate adjustment. ACE inhibitors sive drug treatment, total and high-density lipoprotein decreased total cholesterol, triglycerides, apoprotein B (HDL) cholesterol, triglyceride, apoproteins A-I and B, and LpE:B; and this effect remained after multivariate lipoparticles LpA-I,
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • Calcium Channel Blockers
    Calcium Channel Blockers Summary In general, calcium channel blockers (CCBs) are used most often for the management of hypertension and angina. There are 2 classes of CCBs: the dihydropyridines (DHPs), which have greater selectivity for vascular smooth muscle cells than for cardiac myocytes, and the non-DHPs, which have greater selectivity for cardiac myocytes and are used for cardiac arrhythmias. The DHPs cause peripheral edema, headaches, and postural hypotension most commonly, all of which are due to the peripheral vasodilatory effects of the drugs in this class of CCBs. The non-DHPs are negative inotropes and chronotropes; they can cause bradycardia and depress AV node conduction, increasing the risk of heart failure exacerbation, bradycardia, and AV block. Clevidipine is a DHP calcium channel blocker administered via continuous IV infusion and used for rapid blood pressure reductions. All CCBs are substrates of CYP3A4, but both diltiazem and verapamil are also inhibitors of 3A4 and have an increased risk of drug interactions. Verapamil also inhibits CYP2C9, CYP2C19, and CYP1A2. Pharmacology CCBs selectively inhibit the voltage-gated L-type calcium channels on cardiac myocytes, vascular smooth muscle cells, and cells within the sinoatrial (SA) and atrioventricular (AV) nodes, preventing influx of extracellular calcium. CCBs act by either deforming the channels, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the major cellular calcium store, the endoplasmic reticulum. Calcium influx via these channels serves for excitation-contraction coupling and electrical discharge in the heart and vasculature. A decrease in intracellular calcium will result in inhibition of the contractile process of the myocardial smooth muscle cells, resulting in dilation of the coronary and peripheral arterial vasculature.
    [Show full text]
  • The Truth About Drug Fever Committee Met May 17, 2011
    Volume 25, Number 6 June 2011 Drugs & Therapy B N U N L N L N E N T N I N N ADVERSE DRUG REACTIONS FORMULARY UPDATE The Pharmacy and Therapeutics The truth about drug fever Committee met May 17, 2011. 4 products were added in the Formu- t is estimated that about 3–7% of antimicrobials (median 6 days). Cardiac lary; 2 were deleted and designated I febrile episodes are attributed to drug and central nervous system medica- nonformulary and not available. 1 reactions; however, the true incidence is tions can induce fever at a much slower interchange was approved, while 3 unknown due to underreporting and fre- interval, median of 10 and 16 days after criteria for uses were changed. quent misdiagnosis.1 In the hospitalized initiation, respectively. patient, the most common presentation Fever patterns may present as a for drug fever is a patient with a resolv- continuous fever (temperature does not ing infection, on antimicrobial therapy, vary), remittent fever (where tempera- ◆ ADDED and after initial defervescence. Fever in tures vary, but are consistently elevat- Acetaminophen IV this patient can result in the over-utili- ed), intermittent fever (with normal (Ofirmev® by Cadence zation of antimicrobials and the addition temperatures in between), or the most Pharmaceuticals)* of agents to treat an infection that is not common: hectic fever (combination of 4 *Restricted present. This could potentially cause remittent and intermittent). Degree more adverse effects and further contrib- of pyrexia tends to range from 38.8°C Carglumic Acid ute to antimicrobial resistance. (102°F) to 40°C (104°F) but has been ® (Carbaglu by Orphan Europe) One study evaluating 51 episodes reported as high as 42.8°C (109°F).
    [Show full text]
  • Adult Intravenous Medications
    Revised 9/08 ADULT INTRAVENOUS MEDICATIONS STANDARD AND MAXIMUM ALLOWABLE CONCENTRATIONS, GUIDELINES FOR CONTINUOUS OR TITRATED INFUSIONS MEDICATION STANDARD MAXIMUM CONC./ DOSING MONITORING/COMMENTS ADMIXTURE INFUSION INSTRUCTIONS Adenosine 6 mg/2 mL vial Give undiluted directly into 6 mg initially. If SVT not ECG, heart rate, blood pressure (Adenocard®) (3 mg/mL) given undiluted vein over 1-2 seconds. resolved in 1-2 minutes, may Administer as proximal as follow with 12 mg dose. If Extremely short half life: possible to trunk (i.e., not in not resolved in 1-2 minutes, < 10 seconds Slows conduction time through the AV node, interrupting the re-entry lower arm, hand, lower leg, may follow with an Not effective for converting A. pathways through the AV node, or foot). If administered additional 12 mg dose. flutter, A. fib, or ventricular restoring normal sinus rhythm. through IV line, administer tachycardia. as close to pts heart as Contraindicated if symptomatic Onset of action: immediate Duration: seconds possible. NS flush must be bradycardia, sick sinus given rapidly, immediately syndrome, 2nd or 3rd degree AV following injection of block (unless pt. has functioning adenosine pacemaker) Amiodarone Load: Dilute 150 mg (3mL) in Peripheral line: Up to 2 Load: 150 mg/100 mL over Telemetry monitoring, BP (Cordarone®) 100 mL D5W (1.5 mg/mL) mg/mL 10 minutes. (hypotension occurs frequently (PVC bag suitable for loading (Not to eXceed 30 mg/mL) with initial rates), HR Antiarrhythmic agent that dose) (Concentrations over 2 (arrhythmias: AV block, depresses conduction velocity, mg/mL administered for THEN bradycardia, VT/VF, torsades de slows AV node conduction, raises Maintenance infusion: longer than 1 hour must be pointes), electrolytes the threshold for VF, and eXhibits Dilute 900 mg (18 mL) in infused via central line) Infusion: 1 mg/min for 6 some α and β blockade activity.
    [Show full text]
  • Information for the Patient Nicardipine 10 Mg/10 Ml Solution for Injection Nicardipine Hydrochloride
    Package leaflet: Information for the patient Nicardipine 10 mg/10 ml solution for injection Nicardipine hydrochloride Read all of this leaflet carefully before you are given this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is “Nicardipine 10 mg/10 ml solution for injection” but in the rest of the leaflet it will be called as ‘Nicardipine solution for injection’. What is in this leaflet 1. What Nicardipine solution for injection is and what it is used for 2. What you need to know before you are given Nicardipine solution for injection 3. How to take Nicardipine solution for injection 4. Possible side effects 5. How to store Nicardipine solution for injection 6. Contents of the pack and other information 1. What Nicardipine solution for injection is and what it is used for Nicardipine solution for injection contains the active substance Nicardipine hydrochloride, which belongs to a group of medicines called calcium channel blockers. Nicardipine solution for injection is used to treat very severe high blood pressure. It can also be used to control high blood pressure after an operation. You must talk to a doctor if you do not feel better or if you feel worse. 2. What you need to know before you are given Nicardipine solution for injection Do not take Nicardipine solution for injection: • If you are allergic to Nicardipine or any of the other ingredients of this medicine (listed in section 6) • If you have chest pain • If your high blood pressure is because of narrowing of a heart valve or other defects in the heart • If you have had a heart attack in the last eight days • If you have been told by your doctor that you have an intolerance to some sugars.
    [Show full text]
  • Wo 2009/139817 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 19 November 2009 (19.11.2009) WO 2009/139817 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/4709 (2006.01) C07D 405/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) Number: International Application CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, PCT/US2009/002391 EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, 15 April 2009 (15.04.2009) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, (25) Filing Language: English NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, (26) Publication Language: English SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/045,142 15 April 2008 (15.04.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): SAR- GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, CODE CORPORATION [US/US]; Suite 505, 343 San- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, some Street, San Francisco, CA 94104 (US).
    [Show full text]
  • Hikma Launches Nicardipine Hydrochloride Premixed Injection in Ready to Use Bags
    Press Release Hikma launches Nicardipine Hydrochloride premixed injection in ready to use bags London, 4 May 2020 – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, has launched Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection bags in 200mL, the generic version of Cardene®1, in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc. Nicardipine Hydrochloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. For prolonged control of blood pressure, patients are transferred to oral medication as soon as their clinical condition permits. According to IQVIA, US sales of Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection, 200mL, were approximately $82 million in the 12 months ending January 2020. “Nicardipine Hydrochloride Injection is an important medicine used to treat hypertension and Hikma is proud to introduce the first generic Nicardipine in ready to use bags,” said Riad Mishlawi, President of Injectables. “Hikma also markets Nicardipine in 10mL vials and we are pleased to expand our portfolio with this launch, broadening the choice of medicines available to hospitals.” Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product. -- ENDS -- Enquiries Hikma Pharmaceuticals PLC Susan Ringdal +44 (0)20 7399 2760/ +44 7776 477050 EVP, Strategic Planning and Global Affairs [email protected] Steve Weiss +1 732 720 2830/ +1 732 788 8279 David Belian +1 732 720 2814/+1 848 254 4875 US Communications and Public Affairs [email protected] About Hikma (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P) 1 Cardene® is a registered trademark of Baxter International Inc.
    [Show full text]
  • October/November 2019 Official Publicationof the Emergency
    ResidentOfficial Publication of the Emergency Medicine Residents’ Association October/November 2019 VOL 46 / ISSUE 5 years ENVISION PHYSICIAN SERVICES HAS GIVEN ME ... THE SUPPORT TO EXCEL AND THE AUTONOMY TO THRIVE RICH LOGUE, MD, FACEP EMERGENCY MEDICINE Why EM Residents choose Envision Physician Services ■ Professional Development and Career Advancement ■ Employment Flexibility: Full-Time, Part-Time, moonlighting and Envoy Team. Employed and Independent Contractor options ■ Practice Variety: Coast-to-coast opportunities at well-recognized hospitals and health systems ■ Unparalleled practice support ■ Earn While You Learn Program*: Provides senior residents with $2,500/month while you complete your residency *This program is both site and specialty-specific. 844.307.1218 EVPS.com/EMRA2019 Visit us at ACEP19 Booth #811 EMRA-fied and Proud 45 Years of Resident-Driven Publications Tommy Eales, DO Editor-in-Chief, EM Resident Indiana University @tommyeales s we celebrate the 45th anniversary of EMRA by Arecognizing 45 exceptional young leaders in the specialty of emergency medicine, it’s worth taking a step back and reflecting on one of the greatest accomplishments of the organization. Of course, we’re talking about EMRA publications. Since its first print-only newsletter iterations, EM Resident has grown into the largest resident-led publication in the country, with nearly 20,000 individual print subscribers and more than 30,000 unique monthly visitors to the online edition. We earned recognition on a national stage this year for our plea to address gun violence in America, winning the highest honors among a pool of entries that included commentary from U.S. ambassadors and massive, influential groups such as the AARP.
    [Show full text]
  • Pediatric Guidelines for IV Medication Administration
    Pediatric Guidelines for IV Medication Administration Approved For Usual Dosing and Comments Concent- Drug Administration ICU Telemetry Acute IV ration IVP ED Required Care Infusion Acetazolamide X X X Dilute to 5-10 mg/kg/dose MR q 8 or 6 hrs. Monitor serum electrolytes (Diamox®) MAX of MAX dose: 25 mg/kg/dose up to 500 mg/dose 100 mg/mL MAX Rate: IVP over 1 minute. Acetylcysteine X X X 30 gm/1000 Requires toxicology approval. When used in acetaminophen overdose, (Acetadote®) Bolus Infusion mL Bolus: 150mg/kg over 1 hr. monitor serum acetaminophen concentrations; only (30 mg/mL) Maintenance: 15-7.5mg/kg/hr. See dosing protocol or monitor LFTs. Bolus doses, monitor for + infusion contact pharmacy for weight-based protocol. hypotension, flushing, anaphylaxis Bolus doses must be completed in critical care areas only. Maintenance IV infusions may be continued or initiated in acute care areas. Acyclovir X X X Diluted to Infusion over 60-90 minutes. Dose: 5-20 mg/kg/dose q Patient should be well hydrated to prevent <5 mg/mL 8hrs. nephrotoxicity. Monitor urine output, Scr. Adenosine X X X X 6 mg/2 mL. DOSE:0.05-0.1 mg/kg up to 6 mg over 1-2 seconds Restriction: In acute care areas, doses must (Adenocard®) See (3mg/ml) followed by rapid NS flush. May increase dose by 0.1- be administered by a physician. 0.2 mg/kg q2 minutes up to 12 mg/dose every 1-2 mins Communication with the ICU team prior to restriction . till termination of arrhythmia to a MAX CUM dose of adenosine administration is required.
    [Show full text]
  • Intravenous Nicardipine Its Use in the Short-Term Treatment of Hypertension and Various Other Indications
    Drugs 2006; 66 (13): 1755-1782 ADIS DRUG EVALUATION 0012-6667/06/0013-1755/$44.95/0 © 2006 Adis Data Information BV. All rights reserved. Intravenous Nicardipine Its Use in the Short-Term Treatment of Hypertension and Various Other Indications Monique P. Curran, Dean M. Robinson and Gillian M. Keating Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: D.R. Abernethy, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA; A.T. Cheung, Department of Anesthesia, University of Pennsylvania, Philadelphia, Pennsylvania, USA; M.A Ezzeddine, Department of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, USA; M.E. Goldberg, Cooper University Hospital, Camden, New Jersey, USA; M. Mitsnefes, Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; C.J. Pepine, University of Florida College of Medicine, Gainesville, Florida, USA; D.H. Rhoney, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State, Detroit, Michigan, USA; J.I. Suarez, University Hospitals of Cleveland, Cleveland, Ohio, USA; J. Varon, The University of Texas Health Science Center, Houston, Texas, USA. Data Selection Sources: Medical literature published in any language since 1980 on ‘nicardipine’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: MEDLINE and EMBASE search terms were ‘nicardipine’ and ‘intravenous’. AdisBase search terms were ‘nicardipine’ and (‘intravenous’ or ‘IV’ in title).
    [Show full text]